• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

    10/16/24 6:43:00 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

    The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/kzh3s376. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations.

    The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BI945e651d9e5f40acbfaec616e1b85b4e

    About Veracyte

    Veracyte (NASDAQ:VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241016729306/en/

    Get the next $VCYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will Veracyte release its third quarter 2024 financial results?

      Veracyte, Inc. plans to release its financial results for the third quarter of 2024 on November 6, 2024, after the market closes.

    • What time is the conference call scheduled to discuss the financial results?

      A conference call and webcast to discuss these results and provide a business update will be held on November 6, 2024, at 4:30 p.m. Eastern Time.

    • How can investors access the conference call and its replay?

      The conference call will be accessible via a live webcast on Veracyte's website and will also be available for replay afterward.

    • What is the primary focus of Veracyte as a diagnostics company?

      Veracyte is a global diagnostics company focused on transforming cancer care through high-performing diagnostic tests and deep genomic and clinical data analysis.

    • How can participants register for the conference call?

      Investors can register for the conference call by visiting the provided registration link on Veracyte's announcement.

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings